Ad
related to: bristol-myers squibbscbn.org has been visited by 10K+ users in the past month
Search results
Bristol Myers Squibb’s Breyanzi gains FDA approval for lymphoma
Pharmaceutical Technology via Yahoo Finance· 1 hour agoBristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration for...
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Zacks via Yahoo Finance· 21 hours agoBristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it...
Bristol-Myers Squibb (NYSE:BMY) Shares Down 1.1%
ETF DAILY NEWS· 6 days agoShares of Bristol-Myers Squibb (NYSE:BMY – Get Free Report) fell 1.1% during trading on Thursday . The company traded as low as $41.58 and last traded at $41.89. 3,501,801 shares changed hands ...
Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking - Bristol-Myers Squibb...
Benzinga· 17 hours agoLoading... Loading... Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb BMY , and it's something market players shouldn't ignore. Our tracking of public options ...
US FDA expands use of Bristol's cell therapy to treat rare blood cancer
Reuters via AOL· 18 hours ago(Reuters) -Bristol Myers Squibb said on Thursday the U.S. FDA had allowed expanded use of its cell...
Q2 2025 Earnings Estimate for Bristol-Myers Squibb Issued By Zacks Research (NYSE:BMY)
ETF DAILY NEWS· 3 days agoBristol-Myers Squibb (NYSE:BMY – Free Report) – Investment analysts at Zacks Research raised their Q2 2025 earnings estimates for shares of Bristol-Myers Squibb in a research report issued on ...
Bristol-Myers Squibb Co. [BMY] Investment Appeal on the Rise – Knox Daily
Knox Daily· 2 days agoBristol-Myers Squibb Co.’s filing revealed that its Chief Executive Officer BOERNER CHRISTOPHER S. acquired Company’s shares for reported $99560.0 on Dec 05 ’23. In the deal valued at $49.78 ...
Bristol Myers Squibb checks 'yes' on another Prothena neurodegenerative therapy
FierceBiotech· 2 days agoBristol Myers Squibb is again dipping into the well of therapies being developed by Prothena, this...
Bristol Myers Squibb Shares Cross 6% Yield Mark
Forbes· 2 days agoIn trading on Wednesday, shares of Bristol Myers Squibb were yielding above the 6% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands as low as $39.94 on ...
Bristol Myers (BMY) Gets EC Nod for Opdivo Label Expansion
Zacks via Yahoo Finance· 18 hours agoBristol Myers' (BMY) Opdivo combination regimen receives the European Commission's approval for the...